Skip to main content
Open Access Publications from the University of California

Influence of a single course of antenatal betamethasone on the maternal-fetal insulin-IGF-GH axis in singleton pregnancies

  • Author(s): Ahmad, I
  • Beharry, KDA
  • Valencia, A M
  • Cho, S
  • Guajardo, L
  • Nageotte, M P
  • Modanlou, Houchang D
  • et al.

Objective: We examined the hypothesis that a single course of antenatal betamethasone influences the maternal-fetal insulin-IGF-GH axis. Design: A prospective, observational, pilot study consisting of four groups of pregnant women: (1) received betamethasone and delivered 2 weeks post treatment; (III) untreated women who delivered 37 weeks (term controls). Maternal and mixed umbilical cord blood was collected at delivery and analyzed for insulin, glucose, IGF-I IGF-II, IGFBP-1, IGFBP-3, GH and GHBP. Results: Betamethasone increased maternal insulin, glucose and IGF-I levels without affecting IGFBPs. In the fetal compartment, betamethasone treatment was associated with a delayed suppressive effect on GH and a sustained suppressive effect on IGF-II levels. There were no differences in infant size or neonatal morbidities between patients who delivered 2 weeks post betamethasone treatment. In Group IV, birth weight correlated positively with cord IGF-I levels (r(2) = 0.41, p = 0.0098) and negatively with cord IGFBP-1 levels (r(2) = 0.51, p = 0.0039), and ponderal index correlated negatively with cord IGFBP-1 levels (r(2) = 0.27, p < 0.05). Conclusions: A single course of antenatal betamethasone influences the maternal-fetal insulin-IGF-GH axis, particularly fetal TGF-II levels, without measurable anthropornetric changes at birth. Whether these effects have implications beyond the neonatal period remains to be determined. (c) 2006 Elsevier Ltd. All rights reserved.

Many UC-authored scholarly publications are freely available on this site because of the UC Academic Senate's Open Access Policy. Let us know how this access is important for you.

Main Content
Current View